Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)

MLA

Paul Scigalla, et al. “Results of a Phase II Trial of S-1 as First-Line Treatment of Metastatic Pancreatic Cancer (CESAR-Study Group).” Investigational New Drugs, vol. 30, Apr. 2011, pp. 1184–92. EBSCOhost, https://doi.org/10.1007/s10637-011-9665-x.

APA

Paul Scigalla, Jochen Schuette, Beate Schultheis, Kaku Saito, Ullrich Graeven, Max E. Scheulen, Dirk Strumberg, Rainer Lipp, Axel-Rainer Hanauske, & Lothar Bergmann. (2011). Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Investigational New Drugs, 30, 1184–1192. https://doi.org/10.1007/s10637-011-9665-x

Chicago

Paul Scigalla, Jochen Schuette, Beate Schultheis, Kaku Saito, Ullrich Graeven, Max E. Scheulen, Dirk Strumberg, Rainer Lipp, Axel-Rainer Hanauske, and Lothar Bergmann. 2011. “Results of a Phase II Trial of S-1 as First-Line Treatment of Metastatic Pancreatic Cancer (CESAR-Study Group).” Investigational New Drugs 30 (April): 1184–92. doi:10.1007/s10637-011-9665-x.